EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative products based on the NexACT® drug delivery technology, today announced that it has been approved by the State of New Jersey to sell a portion of its state tax credits and net operating losses (NOLs) pursuant to the Technology Tax Certificate Transfer Program. Specifically, the Company has been approved to sell $1,053,547 in 2008.
